Medicare Program; Town Hall Meeting on the Fiscal Year 2026 Applications for New Medical Services and Technologies Add-On Payments, 74962-74964 [2024-20791]
Download as PDF
74962
Federal Register / Vol. 89, No. 178 / Friday, September 13, 2024 / Notices
living with HIV (PLHIV). Funding
amounts for years 2–5 will be set at
continuation.
The period for this award will be
January 1, 2025, through September 29,
2029.
FOR FURTHER INFORMATION CONTACT:
Vance Brown, Global Health Center,
Centers for Disease Control and
Prevention, 351 Independence Avenue,
P.O Box 320065, Lusaka, Zambia,
Telephone: +260–761–428–720, email:
vhu7@cdc.gov.
SUPPLEMENTARY INFORMATION: The sole
source award will support the Zambian
Ministry of Health (MOH) to achieve
and sustain HIV epidemic control gains
by providing programmatic oversight,
coordination, and direct service delivery
in the provision of comprehensive HIV/
TB prevention, treatment, and support
services, while strengthening health
systems for sustainability.
NWPHO is the only entity that can
carry out this work, as it is the sole
government institution with the
mandate to support the health service
delivery through capacity building,
systems strengthening and oversight for
HIV program implementation for the
population of the Northwestern
Province (NWP) of Zambia by the
National Public Health Act of Zambia.
NWPHO has been actively
implementing PEPFAR programs
through support provided by USGawarded implementing partners funded
by USAID. The government-togovernment award is only possible to be
executed with NWPHO as the registered
sub-national provincial health authority
in NWP Zambia.
DATES:
khammond on DSKJM1Z7X2PROD with NOTICES
Summary of the Award
Recipient: Northwestern Provincial
Health Office (NWPHO).
Purpose of the Award: The purpose of
this award is to provide NWPHO with
CDC Technical Assistance and financial
support to maintain and sustain the
province’s overall oversight and quality
assurance for the implementation of
high-impact HIV combination
prevention, treatment, and support
services, including clinical,
surveillance, and laboratory services as
well as to identify and mitigate
emerging disease threats for PLHIV. The
award aims to strengthen capacity
development activities, while providing
optimal health systems strengthening in
support of continued and sustainable
HIV epidemic control in Zambia.
Amount of Award: The approximate
year 1 funding amount will be
$4,450,000 in Federal Fiscal Year (FYY)
2025 funds, subject to the availability of
VerDate Sep<11>2014
17:53 Sep 12, 2024
Jkt 262001
funds. Funding amounts for years 2–5
will be set at continuation.
Authority: This program is authorized
under Public Law 108–25 (the United
States Leadership Against HIV AIDS,
Tuberculosis and Malaria Act of 2003)
[22 U.S.C. 7601, et seq.] and Public Law
110–293 (the Tom Lantos and Henry J.
Hyde United States Global Leadership
Against HIV/AIDS, Tuberculosis, and
Malaria Reauthorization Act of 2008),
and Public Law 113–56 (PEPFAR
Stewardship and Oversight Act of 2013).
Period of Performance: January 1,
2025, through September 29, 2029.
Dated: September 4, 2024.
Terrance Perry,
Acting Director, Office of Grants Services,
Centers for Disease Control and Prevention.
[FR Doc. 2024–20790 Filed 9–12–24; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
[CMS–1822–N]
Medicare Program; Town Hall Meeting
on the Fiscal Year 2026 Applications
for New Medical Services and
Technologies Add-On Payments
Centers for Medicare &
Medicaid Services (CMS), Department
of Health and Human Services (HHS).
ACTION: Notice of meeting.
AGENCY:
This notice announces a town
hall meeting in accordance with the
Social Security Act (the Act) to discuss
fiscal year (FY) 2026 applications for
add-on payments for new medical
services and technologies under the
hospital inpatient prospective payment
system (IPPS). Interested parties are
invited to this virtual meeting to present
their comments, recommendations, and
data regarding whether the FY 2026 new
medical services and technologies
applications meet the substantial
clinical improvement criterion.
DATES:
Meeting Dates: The New Technology
Town Hall meeting announced in this
notice will be held virtually on
Wednesday, December 11, 2024, and
Thursday, December 12, 2024 (the
number of presentations will determine
if a second day for the meeting is
necessary; see the SUPPLEMENTARY
INFORMATION section for details
regarding the second day of the meeting
and the posting of the final schedule).
The New Technology Town Hall
meeting will begin each day at 9 a.m.
SUMMARY:
PO 00000
Frm 00096
Fmt 4703
Sfmt 4703
eastern standard time (EST) and checkin via online platform will begin at 8:30
a.m. EST.
Deadline for Registration of Presenters
at the New Technology Town Hall
Meeting: The deadline to register to
present at the New Technology Town
Hall meeting is 5 p.m., EST on Monday,
November 4, 2024.
Deadline for Submission of Agenda
Item(s) or Written Comments for the
New Technology Town Hall Meeting:
Written comments and agenda items
(public comments to be delivered at the
New Technology Town Hall meeting)
for discussion at the New Technology
Town Hall meeting, including agenda
items by presenters (presentation slide
decks), must be received by 5 p.m. EST
on Tuesday, November 12, 2024.
Deadline for Requesting Special
Accommodations: The deadline to
submit requests for special
accommodations is 5 p.m., EST on
Tuesday, November 12, 2024.
Deadline for Submission of Written
Comments after the New Technology
Town Hall Meeting for Consideration in
the Fiscal Year (FY) 2026 Hospital
Inpatient Prospective Payment System/
Long Term Care PPS (IPPS/LTCH PPS)
Proposed Rule: Individuals may submit
written comments after the New
Technology Town Hall meeting, as
specified in the ADDRESSES section of
this notice, on whether the service or
technology represents a substantial
clinical improvement. These comments
must be received by 5 p.m. EST on
Monday, December 16, 2024, to ensure
consideration in the FY 2026 IPPS/
LTCH PPS proposed rule.
ADDRESSES:
Meeting Location: The New
Technology Town Hall meeting will be
held virtually via live stream technology
or webinar and listen-only via toll-free
teleconference. Live stream or webinar
and teleconference dial-in information
will be provided through an upcoming
listserv/email notice and will appear on
the final meeting agenda, which will be
posted on the New Technology website
when available at: https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
newtech.html. Continue to check the
website for updates.
Registration and Special
Accommodations: Individuals wishing
to present at the meeting must follow
the instructions located in section III. of
this notice. Individuals who need
special accommodations should send an
email to newtech@cms.hhs.gov.
Submission of Agenda Item(s) or
Written Comments for the New
Technology Town Hall Meeting: Each
E:\FR\FM\13SEN1.SGM
13SEN1
Federal Register / Vol. 89, No. 178 / Friday, September 13, 2024 / Notices
presenter must submit at least one
agenda item for presentation regarding
whether a FY 2026 application meets
the substantial clinical improvement
criterion. Other items such as written
comments, questions or other
statements must not exceed three singlespaced typed pages and may be sent via
email to newtech@cms.hhs.gov.
FOR FURTHER INFORMATION CONTACT:
Drew Kasper, (410) 786–8926,
drew.kasper@cms.hhs.gov and
newtech@cms.hhs.gov.
SUPPLEMENTARY INFORMATION:
khammond on DSKJM1Z7X2PROD with NOTICES
I. Background on the Add-On Payments
for New Medical Services and
Technologies Under the IPPS
Effective for discharges beginning on
or after October 1, 2001, section
1886(d)(5)(K)(i) of the Act requires the
Secretary to establish (after notice and
opportunity for public comment) a
mechanism to recognize the costs of
new services and technologies under the
hospital inpatient prospective payment
system (IPPS). In addition, section
1886(d)(5)(K)(vi) of the Act specifies
that a medical service or technology will
be considered ‘‘new’’ if it meets criteria
established by the Secretary (after notice
and opportunity for public comment).
For further discussion on the new
technology add-on payment criteria, we
refer readers to the new technology addon payment final rule (66 FR 46912,
September 7, 2001), as well as the FY
2012 IPPS/LTCH PPS final rule (76 FR
51572 through 51574), the FY 2020
IPPS/LTCH PPS final rule (84 FR 42288
through 42300), and the FY 2021 IPPS/
LTCH PPS final rule (85 FR 58736
through 58742).
As finalized in the FY 2020 and FY
2021 IPPS/LTCH PPS final rules,
technologies which are eligible for the
alternative new technology pathway for
transformative new devices or the
alternative new technology pathway for
certain antimicrobials do not need to
meet the requirement under 42 CFR
412.87(b)(1) that the technology
represent an advance that substantially
improves, relative to technologies
previously available, the diagnosis or
treatment of Medicare beneficiaries.
These medical devices or products will
also be considered not substantially
similar to an existing technology for
purposes of new technology add-on
payment under the IPPS. See the FY
2020 IPPS/LTCH PPS final rule (84 FR
42292 through 42297) and the FY 2021
IPPS/LTCH PPS final rule (85 FR 58737
through 58739) for additional
information.
In the FY 2020 IPPS/LTCH PPS final
rule (84 FR 42289 through 42292), we
VerDate Sep<11>2014
17:53 Sep 12, 2024
Jkt 262001
codified in our regulations at § 412.87
the following aspects of how we
evaluate substantial clinical
improvement for purposes of new
technology add-on payments under the
IPPS to determine if a new technology
meets the substantial clinical
improvement requirement:
• The totality of the circumstances is
considered when making a
determination that a new medical
service or technology represents an
advance that substantially improves,
relative to services or technologies
previously available, the diagnosis or
treatment of Medicare beneficiaries.
• A determination that a new medical
service or technology represents an
advance that substantially improves,
relative to services or technologies
previously available, the diagnosis or
treatment of Medicare beneficiaries
means—
++ The new medical service or
technology offers a treatment option for
a patient population unresponsive to, or
ineligible for, currently available
treatments;
++ The new medical service or
technology offers the ability to diagnose
a medical condition in a patient
population where that medical
condition is currently undetectable or
offers the ability to diagnose a medical
condition earlier in a patient population
than allowed by currently available
methods, and there must also be
evidence that use of the new medical
service or technology to make a
diagnosis affects the management of the
patient; or
++ The use of the new medical service
or technology significantly improves
clinical outcomes relative to services or
technologies previously available as
demonstrated by one or more of the
following:
—A reduction in at least one clinically
significant adverse event, including a
reduction in mortality or a clinically
significant complication.
—A decreased rate of at least one
subsequent diagnostic or therapeutic
intervention (for example, due to
reduced rate of recurrence of the
disease process).
—A decreased number of future
hospitalizations or physician visits.
—A more rapid beneficial resolution of
the disease process treatment
including, but not limited to, a
reduced length of stay or recovery
time; an improvement in one or more
activities of daily living; an improved
quality of life; or a demonstrated
greater medication adherence or
compliance.
PO 00000
Frm 00097
Fmt 4703
Sfmt 4703
74963
++ The totality of the circumstances
otherwise demonstrates that the new
medical service or technology
substantially improves, relative to
technologies previously available, the
diagnosis or treatment of Medicare
beneficiaries.
• Evidence from the following
published or unpublished information
sources from within the United States or
elsewhere may be sufficient to establish
that a new medical service or
technology represents an advance that
substantially improves, relative to
services or technologies previously
available, the diagnosis or treatment of
Medicare beneficiaries: Clinical trials,
peer reviewed journal articles; study
results; meta-analyses; consensus
statements; white papers; patient
surveys; case studies; reports;
systematic literature reviews; letters
from major healthcare associations;
editorials and letters to the editor; and
public comments. Other appropriate
information sources may be considered.
• The medical condition diagnosed or
treated by the new medical service or
technology may have a low prevalence
among Medicare beneficiaries.
• The new medical service or
technology may represent an advance
that substantially improves, relative to
services or technologies previously
available, the diagnosis or treatment of
a subpopulation of patients with the
medical condition diagnosed or treated
by the new medical service or
technology.
Section 1886(d)(5)(K)(viii) of the Act
requires that as part of the process for
evaluating new medical services and
technology applications, the Secretary
shall do the following:
• Provide for public input regarding
whether a new service or technology
represents an advance in medical
technology that substantially improves
the diagnosis or treatment of Medicare
beneficiaries before publication of a
proposed rule.
• Make public and periodically
update a list of all the services and
technologies for which an application is
pending.
• Accept comments,
recommendations, and data from the
public regarding whether the service or
technology represents a substantial
improvement.
• Provide for a meeting at which
organizations representing hospitals,
physicians, manufacturers, and any
other interested party may present
comments, recommendations, and data
to the clinical staff of CMS as to whether
the service or technology represents a
substantial improvement before
publication of a proposed rule.
E:\FR\FM\13SEN1.SGM
13SEN1
74964
Federal Register / Vol. 89, No. 178 / Friday, September 13, 2024 / Notices
The opinions and presentations
provided during this meeting will assist
us as we evaluate the new medical
services and technology applications for
FY 2026.
II. New Technology Town Hall Meeting
Format and Conference Call
Information
khammond on DSKJM1Z7X2PROD with NOTICES
A. Format of the Town Hall Meeting
As noted in section I. of this notice,
we are required to provide for a meeting
at which organizations representing
hospitals, physicians, manufacturers,
and any other interested party may
present comments, recommendations,
and data to the clinical staff of CMS
concerning whether the service or
technology represents a substantial
clinical improvement. This meeting will
allow for a discussion of the substantial
clinical improvement criterion for the
FY 2026 applications for new
technology add-on payments.
Information regarding the applications
can be found on our website at https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient
PPS/newtech.html.
The majority of the meeting will be
reserved for presentations of comments,
recommendations, and data from
registered presenters. The time for each
presentation will be approximately 10
minutes, with additional time reserved
for questions, and will be based on the
number of presentations. Individuals
who would like to present must register
and submit their agenda item(s) via
email to newtech@cms.hhs.gov by the
dates specified in the DATES section of
this notice.
Depending on the number of
presentations, we will determine if a
second meeting day is necessary. The
final schedule for the New Technology
Town Hall meeting will be posted on
the CMS website at https://www.cms.gov/
Medicare/Medicare-Fee-for-ServicePayment/AcuteInpatientPPS/
newtech.html by November 25, 2024 to
inform the public of the number of days
of the meeting.
In addition, written comments will
also be accepted and presented at the
meeting if they are received via email to
newtech@cms.hhs.gov by the date
specified in the DATES section of this
notice. Written comments may also be
submitted after the meeting for our
consideration. If the comments are to be
considered before the publication of the
FY 2026 IPPS/LTCH PPS proposed rule,
the comments must be received via
email to newtech@cms.hhs.gov by the
date specified in the DATES section of
this notice.
VerDate Sep<11>2014
17:53 Sep 12, 2024
Jkt 262001
B. Conference Call and Webinar
Information
purposes of publication in the Federal
Register.
As noted previously, the New
Technology Town Hall meeting will be
held virtually. There will be an option
to participate in the New Technology
Town Hall Meeting via webinar and a
toll-free teleconference phone line.
Information on the option to participate
via webinar and a teleconference dial-in
will be provided through an upcoming
listserv/email notice to registrants and
will appear on the final meeting agenda,
which will be posted on the New
Technology website at: https://
www.cms.gov/Medicare/Medicare-Feefor-Service-Payment/AcuteInpatient
PPS/newtech.html. Continue to check
the website for updates.
Chyana Woodyard,
Federal Register Liaison, Centers for Medicare
& Medicaid Services.
C. Disclaimer
We cannot guarantee reliability for a
webinar.
III. Registration Instructions
IV. Collection of Information
This document does not impose
information collection requirements,
that is, reporting, recordkeeping, or
third-party disclosure requirements.
Consequently, there is no need for
review by the Office of Management and
Budget under the authority of the
Paperwork Reduction Act of 1995 (44
U.S.C. chapter 35).
The Administrator of the Centers for
Medicare & Medicaid Services (CMS),
Chiquita Brooks-LaSure, having
reviewed and approved this document,
authorizes Chyana Woodyard, who is
the Federal Register Liaison, to
electronically sign this document for
Frm 00098
Fmt 4703
Sfmt 4703
BILLING CODE 4120–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
[Assistance Listing Number: 93.652]
Announcement of the Intent To Award
a Within Scope Awarding AgencyInitiated Non-Competitive Supplement
With Extension to the American Public
Human Services Association for the
Association of Administrators of the
Interstate Compact on the Placement
of Children (AAICPC) in Washington,
DC
Children’s Bureau (CB),
Administration for Children and
Families (ACF), Department of Health
and Human Services (HHS).
ACTION: Notice of Issuance of a within
scope awarding agency-initiated noncompetitive supplement with extension.
AGENCY:
The Division of New Technology in
CMS is coordinating the meeting
registration for the New Technology
Town Hall meeting on substantial
clinical improvement. While there is no
registration fee, individuals planning to
present at the New Technology Town
Hall meeting must register to present.
Registration for presenters may be
completed by sending an email to
newtech@cms.hhs.gov, by the date
specified in the DATES section of this
notice. Please include the name and
email address of the presenter(s), as well
as address, telephone number, and the
name of the technology for which they
will be presenting.
Registration for attendees not
presenting at the meeting is not
required.
PO 00000
[FR Doc. 2024–20791 Filed 9–12–24; 8:45 am]
The ACF, ACYF, CB, Division
of Capacity Building announces the
intent to award a within scope awarding
agency-initiated non-competitive
supplement with extension in the
amount of up to $1,600,000, to the
American Public Human Services
Association for its affiliate the
Association of Administrators of the
Interstate Compact on the Placement of
Children (AAICPC) in Washington, DC,
for the further implementation and
support nationally of the National
Electronic Interstate Compact Enterprise
(NEICE) system. The NEICE is an interjurisdictional electronic system to
improve administrative efficiency in
implementing the Interstate Compact on
the Placement of Children (ICPC), a
process that ensures safe and suitable
interstate placements for children in
foster care.
DATES: The proposed period of
performance is September 30, 2024,
through September 29, 2025.
FOR FURTHER INFORMATION CONTACT: June
Dorn, National Adoption Specialist,
Children’s Bureau, Division of Capacity
Building, 330 C St. SW, Suite 3521B,
Washington, DC 20201. Telephone:
(202) 205–9240; Email: June.Dorn@
acf.hhs.gov.
SUPPLEMENTARY INFORMATION: Award
funds will support the continued
SUMMARY:
E:\FR\FM\13SEN1.SGM
13SEN1
Agencies
[Federal Register Volume 89, Number 178 (Friday, September 13, 2024)]
[Notices]
[Pages 74962-74964]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-20791]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
[CMS-1822-N]
Medicare Program; Town Hall Meeting on the Fiscal Year 2026
Applications for New Medical Services and Technologies Add-On Payments
AGENCY: Centers for Medicare & Medicaid Services (CMS), Department of
Health and Human Services (HHS).
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: This notice announces a town hall meeting in accordance with
the Social Security Act (the Act) to discuss fiscal year (FY) 2026
applications for add-on payments for new medical services and
technologies under the hospital inpatient prospective payment system
(IPPS). Interested parties are invited to this virtual meeting to
present their comments, recommendations, and data regarding whether the
FY 2026 new medical services and technologies applications meet the
substantial clinical improvement criterion.
DATES:
Meeting Dates: The New Technology Town Hall meeting announced in
this notice will be held virtually on Wednesday, December 11, 2024, and
Thursday, December 12, 2024 (the number of presentations will determine
if a second day for the meeting is necessary; see the SUPPLEMENTARY
INFORMATION section for details regarding the second day of the meeting
and the posting of the final schedule). The New Technology Town Hall
meeting will begin each day at 9 a.m. eastern standard time (EST) and
check-in via online platform will begin at 8:30 a.m. EST.
Deadline for Registration of Presenters at the New Technology Town
Hall Meeting: The deadline to register to present at the New Technology
Town Hall meeting is 5 p.m., EST on Monday, November 4, 2024.
Deadline for Submission of Agenda Item(s) or Written Comments for
the New Technology Town Hall Meeting: Written comments and agenda items
(public comments to be delivered at the New Technology Town Hall
meeting) for discussion at the New Technology Town Hall meeting,
including agenda items by presenters (presentation slide decks), must
be received by 5 p.m. EST on Tuesday, November 12, 2024.
Deadline for Requesting Special Accommodations: The deadline to
submit requests for special accommodations is 5 p.m., EST on Tuesday,
November 12, 2024.
Deadline for Submission of Written Comments after the New
Technology Town Hall Meeting for Consideration in the Fiscal Year (FY)
2026 Hospital Inpatient Prospective Payment System/Long Term Care PPS
(IPPS/LTCH PPS) Proposed Rule: Individuals may submit written comments
after the New Technology Town Hall meeting, as specified in the
ADDRESSES section of this notice, on whether the service or technology
represents a substantial clinical improvement. These comments must be
received by 5 p.m. EST on Monday, December 16, 2024, to ensure
consideration in the FY 2026 IPPS/LTCH PPS proposed rule.
ADDRESSES:
Meeting Location: The New Technology Town Hall meeting will be held
virtually via live stream technology or webinar and listen-only via
toll-free teleconference. Live stream or webinar and teleconference
dial-in information will be provided through an upcoming listserv/email
notice and will appear on the final meeting agenda, which will be
posted on the New Technology website when available at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html. Continue to check the website for
updates.
Registration and Special Accommodations: Individuals wishing to
present at the meeting must follow the instructions located in section
III. of this notice. Individuals who need special accommodations should
send an email to [email protected].
Submission of Agenda Item(s) or Written Comments for the New
Technology Town Hall Meeting: Each
[[Page 74963]]
presenter must submit at least one agenda item for presentation
regarding whether a FY 2026 application meets the substantial clinical
improvement criterion. Other items such as written comments, questions
or other statements must not exceed three single-spaced typed pages and
may be sent via email to [email protected].
FOR FURTHER INFORMATION CONTACT: Drew Kasper, (410) 786-8926,
[email protected] and [email protected].
SUPPLEMENTARY INFORMATION:
I. Background on the Add-On Payments for New Medical Services and
Technologies Under the IPPS
Effective for discharges beginning on or after October 1, 2001,
section 1886(d)(5)(K)(i) of the Act requires the Secretary to establish
(after notice and opportunity for public comment) a mechanism to
recognize the costs of new services and technologies under the hospital
inpatient prospective payment system (IPPS). In addition, section
1886(d)(5)(K)(vi) of the Act specifies that a medical service or
technology will be considered ``new'' if it meets criteria established
by the Secretary (after notice and opportunity for public comment). For
further discussion on the new technology add-on payment criteria, we
refer readers to the new technology add-on payment final rule (66 FR
46912, September 7, 2001), as well as the FY 2012 IPPS/LTCH PPS final
rule (76 FR 51572 through 51574), the FY 2020 IPPS/LTCH PPS final rule
(84 FR 42288 through 42300), and the FY 2021 IPPS/LTCH PPS final rule
(85 FR 58736 through 58742).
As finalized in the FY 2020 and FY 2021 IPPS/LTCH PPS final rules,
technologies which are eligible for the alternative new technology
pathway for transformative new devices or the alternative new
technology pathway for certain antimicrobials do not need to meet the
requirement under 42 CFR 412.87(b)(1) that the technology represent an
advance that substantially improves, relative to technologies
previously available, the diagnosis or treatment of Medicare
beneficiaries. These medical devices or products will also be
considered not substantially similar to an existing technology for
purposes of new technology add-on payment under the IPPS. See the FY
2020 IPPS/LTCH PPS final rule (84 FR 42292 through 42297) and the FY
2021 IPPS/LTCH PPS final rule (85 FR 58737 through 58739) for
additional information.
In the FY 2020 IPPS/LTCH PPS final rule (84 FR 42289 through
42292), we codified in our regulations at Sec. 412.87 the following
aspects of how we evaluate substantial clinical improvement for
purposes of new technology add-on payments under the IPPS to determine
if a new technology meets the substantial clinical improvement
requirement:
The totality of the circumstances is considered when
making a determination that a new medical service or technology
represents an advance that substantially improves, relative to services
or technologies previously available, the diagnosis or treatment of
Medicare beneficiaries.
A determination that a new medical service or technology
represents an advance that substantially improves, relative to services
or technologies previously available, the diagnosis or treatment of
Medicare beneficiaries means--
++ The new medical service or technology offers a treatment option
for a patient population unresponsive to, or ineligible for, currently
available treatments;
++ The new medical service or technology offers the ability to
diagnose a medical condition in a patient population where that medical
condition is currently undetectable or offers the ability to diagnose a
medical condition earlier in a patient population than allowed by
currently available methods, and there must also be evidence that use
of the new medical service or technology to make a diagnosis affects
the management of the patient; or
++ The use of the new medical service or technology significantly
improves clinical outcomes relative to services or technologies
previously available as demonstrated by one or more of the following:
--A reduction in at least one clinically significant adverse event,
including a reduction in mortality or a clinically significant
complication.
--A decreased rate of at least one subsequent diagnostic or therapeutic
intervention (for example, due to reduced rate of recurrence of the
disease process).
--A decreased number of future hospitalizations or physician visits.
--A more rapid beneficial resolution of the disease process treatment
including, but not limited to, a reduced length of stay or recovery
time; an improvement in one or more activities of daily living; an
improved quality of life; or a demonstrated greater medication
adherence or compliance.
++ The totality of the circumstances otherwise demonstrates that
the new medical service or technology substantially improves, relative
to technologies previously available, the diagnosis or treatment of
Medicare beneficiaries.
Evidence from the following published or unpublished
information sources from within the United States or elsewhere may be
sufficient to establish that a new medical service or technology
represents an advance that substantially improves, relative to services
or technologies previously available, the diagnosis or treatment of
Medicare beneficiaries: Clinical trials, peer reviewed journal
articles; study results; meta-analyses; consensus statements; white
papers; patient surveys; case studies; reports; systematic literature
reviews; letters from major healthcare associations; editorials and
letters to the editor; and public comments. Other appropriate
information sources may be considered.
The medical condition diagnosed or treated by the new
medical service or technology may have a low prevalence among Medicare
beneficiaries.
The new medical service or technology may represent an
advance that substantially improves, relative to services or
technologies previously available, the diagnosis or treatment of a
subpopulation of patients with the medical condition diagnosed or
treated by the new medical service or technology.
Section 1886(d)(5)(K)(viii) of the Act requires that as part of the
process for evaluating new medical services and technology
applications, the Secretary shall do the following:
Provide for public input regarding whether a new service
or technology represents an advance in medical technology that
substantially improves the diagnosis or treatment of Medicare
beneficiaries before publication of a proposed rule.
Make public and periodically update a list of all the
services and technologies for which an application is pending.
Accept comments, recommendations, and data from the public
regarding whether the service or technology represents a substantial
improvement.
Provide for a meeting at which organizations representing
hospitals, physicians, manufacturers, and any other interested party
may present comments, recommendations, and data to the clinical staff
of CMS as to whether the service or technology represents a substantial
improvement before publication of a proposed rule.
[[Page 74964]]
The opinions and presentations provided during this meeting will
assist us as we evaluate the new medical services and technology
applications for FY 2026.
II. New Technology Town Hall Meeting Format and Conference Call
Information
A. Format of the Town Hall Meeting
As noted in section I. of this notice, we are required to provide
for a meeting at which organizations representing hospitals,
physicians, manufacturers, and any other interested party may present
comments, recommendations, and data to the clinical staff of CMS
concerning whether the service or technology represents a substantial
clinical improvement. This meeting will allow for a discussion of the
substantial clinical improvement criterion for the FY 2026 applications
for new technology add-on payments. Information regarding the
applications can be found on our website at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html.
The majority of the meeting will be reserved for presentations of
comments, recommendations, and data from registered presenters. The
time for each presentation will be approximately 10 minutes, with
additional time reserved for questions, and will be based on the number
of presentations. Individuals who would like to present must register
and submit their agenda item(s) via email to [email protected] by the
dates specified in the DATES section of this notice.
Depending on the number of presentations, we will determine if a
second meeting day is necessary. The final schedule for the New
Technology Town Hall meeting will be posted on the CMS website at
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html by November 25, 2024 to inform the
public of the number of days of the meeting.
In addition, written comments will also be accepted and presented
at the meeting if they are received via email to [email protected] by
the date specified in the DATES section of this notice. Written
comments may also be submitted after the meeting for our consideration.
If the comments are to be considered before the publication of the FY
2026 IPPS/LTCH PPS proposed rule, the comments must be received via
email to [email protected] by the date specified in the DATES section
of this notice.
B. Conference Call and Webinar Information
As noted previously, the New Technology Town Hall meeting will be
held virtually. There will be an option to participate in the New
Technology Town Hall Meeting via webinar and a toll-free teleconference
phone line. Information on the option to participate via webinar and a
teleconference dial-in will be provided through an upcoming listserv/
email notice to registrants and will appear on the final meeting
agenda, which will be posted on the New Technology website at: https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/newtech.html. Continue to check the website for
updates.
C. Disclaimer
We cannot guarantee reliability for a webinar.
III. Registration Instructions
The Division of New Technology in CMS is coordinating the meeting
registration for the New Technology Town Hall meeting on substantial
clinical improvement. While there is no registration fee, individuals
planning to present at the New Technology Town Hall meeting must
register to present.
Registration for presenters may be completed by sending an email to
[email protected], by the date specified in the DATES section of this
notice. Please include the name and email address of the presenter(s),
as well as address, telephone number, and the name of the technology
for which they will be presenting.
Registration for attendees not presenting at the meeting is not
required.
IV. Collection of Information
This document does not impose information collection requirements,
that is, reporting, recordkeeping, or third-party disclosure
requirements. Consequently, there is no need for review by the Office
of Management and Budget under the authority of the Paperwork Reduction
Act of 1995 (44 U.S.C. chapter 35).
The Administrator of the Centers for Medicare & Medicaid Services
(CMS), Chiquita Brooks-LaSure, having reviewed and approved this
document, authorizes Chyana Woodyard, who is the Federal Register
Liaison, to electronically sign this document for purposes of
publication in the Federal Register.
Chyana Woodyard,
Federal Register Liaison, Centers for Medicare & Medicaid Services.
[FR Doc. 2024-20791 Filed 9-12-24; 8:45 am]
BILLING CODE 4120-01-P